{
  "authors": [
    {
      "author": "Caterina Longo"
    },
    {
      "author": "Stefania Borsari"
    },
    {
      "author": "Elisa Benati"
    },
    {
      "author": "Elvira Moscarella"
    },
    {
      "author": "Roberto Alfano"
    },
    {
      "author": "Giuseppe Argenziano"
    }
  ],
  "doi": "10.1007/s13555-016-0094-9",
  "publication_date": "2016-02-06",
  "id": "EN114885",
  "url": "https://pubmed.ncbi.nlm.nih.gov/26847171",
  "source": "Dermatology and therapy",
  "source_url": "",
  "licence": "CC BY-NC",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "Dermoscopy and RCM findings in two patients with AK treated with ingenol mebutate confirm that it induces rapid lesion necrosis and specific neutrophil-mediated, antibody-dependent cellular cytotoxicity. Necrosis occurs via mitochondrial membrane disruption, with subsequent eradication of residual tumor cells via transient inflammation. Local skin reactions to ingenol mebutate should be considered part of the drug's mechanism of action rather than an adverse effect."
}